Loading clinical trials...

Transcranial Pulse Stimulation (TPS) for Alzheimer's Disease (AD) | Clinical Trials | Clareo Health

COMPLETEDNA

Transcranial Pulse Stimulation (TPS) for Alzheimer's Disease (AD)

Transcranial Pulse Stimulation for Alzheimer's Disease in an Open Prospective Pilot Study

NCT04333329•Storz Medical AG

View on ClinicalTrials.gov

Summary

This is a prospective open comprehensive proof-of-principle pilot study.

Detailed Description

This is a prospective open comprehensive proof-of-principle pilot study with patients of mild to moderate Alzheimer's Disease who have been treated with transcranial pulse stimulation (TPS)

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinically stable patients with probable Alzheimer's Disease (Diagnosis according to ICD-10 Criteria (F00))
•MMSE ≥ 10: Mild and moderate Alzheimer's Disease according to AWMF Register, S3 Guidelines of DGN 038/013 and DEGAM 035/021
•At least 3 months of stable antidementia therapy or no antidementia therapy necessary (Patients need to continue their standard treatment within the clinical investigation according to the guidelines as TPS is considered an additional treatment to standard therapy)
•Signed written informed consent
•18 years ≤ Age ≤ 85 years
•Monthly pregnancy tests for female patients in childbearing age

Exclusion Criteria

•Non-compliance with the protocol (including CERAD-plus)
•Pregnancy
•Breast-feeding women
•Microbubbles (contrast agents) in application area
•Cerebral pathology unrelated to Alzheimer's disease
•Metallic objects in the head
•Neurosurgical intervention of the brain / Craniotomy
•Cardiac disorders
•History of psychiatric diseases before development of dementia
•Hemophilia or other blood clotting disorders
+2 more criteria

Locations (1)

Rheintalklinik

Bad Krozingen, Baden-Wurttemberg, Germany

Key Dates

Start Date

August 8, 2015

Primary Completion Date

February 15, 2017

Completion Date

February 15, 2017

Last Updated

April 3, 2020

Enrollment

ACTUAL participants

Conditions

Alzheimer Disease

Interventions

NEUROLITH

DEVICE

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

RECRUITINGNA

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 3, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Transcranial Pulse Stimulation (TPS) for Alzheimer's Disease (AD)

Inclusion Criteria

Exclusion Criteria

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Longitudinal Early-onset Alzheimer's Disease Study Protocol

A Study of AMDX-2011P in Participants With Alzheimer's Disease